BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

Core Insights - BiomX has decided to discontinue the Phase 2b trial of BX004 for cystic fibrosis due to high rates of adverse events identified in a safety review by the Data Monitoring Committee [1][2] - The company is focusing on its phage program BX011 for Staphylococcus aureus infections related to diabetic foot infections while implementing cost-cutting measures, including workforce reduction [1][2][3] Company Overview - BiomX is a clinical-stage company developing natural and engineered phage therapies aimed at treating chronic diseases with significant unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]